Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report published on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at $3.40 EPS and FY2028 earnings at $6.41 EPS.

Other research analysts also recently issued reports about the company. Bank of America downgraded Esperion Therapeutics from a buy rating to a neutral rating in a research report on Wednesday, January 3rd. Needham & Company LLC reissued a buy rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Monday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and an average price target of $9.33.

Esperion Therapeutics Stock Down 3.0 %

Shares of NASDAQ ESPR opened at $2.62 on Monday. The business’s 50 day moving average is $2.37 and its two-hundred day moving average is $1.80. The company has a market cap of $484.83 million, a P/E ratio of -1.24 and a beta of 0.82. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.34.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same period in the prior year, the firm earned ($0.76) earnings per share. Sell-side analysts expect that Esperion Therapeutics will post -0.61 earnings per share for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Institutional investors have recently modified their holdings of the company. FMR LLC grew its holdings in shares of Esperion Therapeutics by 30.0% during the 2nd quarter. FMR LLC now owns 8,669 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 2,003 shares in the last quarter. Private Portfolio Partners LLC acquired a new stake in Esperion Therapeutics in the 4th quarter valued at $30,000. Principal Financial Group Inc. acquired a new stake in Esperion Therapeutics in the 1st quarter valued at $49,000. Amalgamated Bank boosted its stake in Esperion Therapeutics by 18.6% in the 4th quarter. Amalgamated Bank now owns 12,490 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,960 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in Esperion Therapeutics in the 1st quarter valued at $65,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.